Interactive Clinical Technologies Incorporated, (ICTI) is pleased to announce two recent promotions.
April 28, 2005, Yardley, PA - Interactive Clinical Technologies Incorporated, (ICTI) is pleased to announce two recent promotions.
Valarie L. Higgins has been appointed Vice President, Clinical Services. Since joining ICTI six years ago, she has served in increasingly important positions in clinical operations management. Her contributions have been instrumental in establishing ICTI's reputation for high-quality customer service. Most recently Ms Higgins was Director, Clinical Services at ICTI. Earlier in her career, she was a Research Assistant for Covance. Ms. Higgins holds a BA in Psychology from Rutgers University.
Marsha B. Rehrer has been promoted to Director, Software Testing Services, from Associate Director. Throughout her career, Ms. Rehrer has held positions of expanding responsibility in software development, quality assurance and operations. Her recent promotion recognizes the value she has brought and will continue to bring to ICTI's growing product base. Ms. Rehrer holds a BS in English from Davis & Elkins College in Elkins, WV.
Richard McCann, President of ICTI, noted. "To continue to provide our clients unparalleled service and software, we need highly qualified, talented individuals at all levels of our company. I am pleased that Val and Marsha will have increased influence on our quality and service."
About ICTI and Almac Sciences
ICTI is a division of Almac Sciences that specializes in interactive solutions to accelerate the clinical trials process and reduce the costs of clinical trials. Our solutions include Interactive Voice Response (iVR) for patient randomization, dosing and clinical supply management; phone-based patient diaries; iTrial EDC for clinical trials data; and forecasting for clinical trials supplies planning.
Almac Sciences and its affiliated companies (CSS (Chemical Synthesis Services), CTS (Clinical Trial Services), ICTI (Interactive Clinical Technologies Incorporated), PDMS (Pharmaceutical Development and Manufacturing Services) and ArraDX (Array Based Diagnostics)) provide a broad range of services across drug discovery, diagnostics, pharmaceutical research and development, manufacture of API, clinical trials and drug product manufacture. US operations are based in Pennsylvania, North Carolina and California. European operations are headquartered in Craigavon, Northern Ireland with additional operations in London and Edinburgh.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.